文献速递血液净化与透析

恩格列净对腹膜透析患者超滤量的影响

Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis.
PubMed 文献 · Kidney Int Rep · 2025-10-10

这项多中心随机双盲安慰剂对照交叉试验纳入40例腹膜透析患者,评估恩格列净10 mg/d治疗8周对每日超滤量的影响。结果显示恩格列净与安慰剂相比未显著改善超滤量(差值-38 ml,95%CI -120至44,P=0.36),提示短期临床效用有限。

要点

  • 恩格列净10 mg/d治疗8周未显著增加腹膜透析患者每日超滤量。
  • 尿糖排泄增加2698 mg/d,但尿量、尿钠及尿蛋白无变化。
  • 亚组分析未发现糖尿病或腹膜转运特性存在异质性。

核心结论

  • 恩格列净未显著改善腹膜透析患者的超滤量,短期临床效用有限。

研究设计与样本

  • 多中心、随机(1:1)、双盲、安慰剂对照交叉试验,40例随机,37例接受治疗并分析。

主要发现

  • 第8周时超滤量变化在恩格列净与安慰剂间无显著差异(-38 ml,95%CI -120至44,P=0.36)。
  • 恩格列净组尿糖排泄增加2698 mg/d(95%CI 343-5052),尿量、尿钠及尿蛋白无变化。
  • 糖尿病或腹膜转运特性亚组未见异质性。
  • 不良事件发生率恩格列净组47%、安慰剂组29%;严重不良事件分别为11%和6%。

临床怎么用

  • 不推荐仅以增加超滤量为目的在腹膜透析患者中使用恩格列净。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) is expressed in the human peritoneum, and preclinical studies suggest that SGLT2 inhibitors may enhance ultrafiltration by reducing glucose absorption from peritoneal dialysis (PD) solutions. This study evaluated whether empagliflozin increases ultrafiltration volume (UFV) in patients on PD. METHODS: In this multicenter, randomized (1:1), double-blind, placebo-controlled crossover trial, patients on PD received empagliflozin (10 mg/d) or placebo for 8 weeks, separated by a 4-week washout period. The primary outcome was the change in daily UFV from baseline to week 8 in each treatment period. RESULTS: Of 40 randomized patients, 37 received treatment and were analyzed. The median age was 66 years, PD duration was 2.8 years, and 46% were female. At baseline, median daily UFV was 476 ml with 4500 ml of glucose-based dialysate. At week 8, change in UFV did not significantly differ between treatments (-38 ml; 95% confidence interval [CI]: -120 to 44; P = 0.36). No heterogeneity was observed in subgroups by diabetes or peritoneal membrane transport characteristics. Empagliflozin had no significant effect on UFV or dialysate glucose or sodium concentrations, assessed by peritoneal equilibration test (PET). Urinary glucose excretion increased by 2698 mg/d (95% CI: 343-5052), without changes in urine volume, sodium, or protein excretion. Adverse events occurred in 47% with empagliflozin and 29% with placebo; serious adverse events occurred in 11% and 6%, respectively. CONCLUSION: Empagliflozin did not significantly improve UFV in patients on PD, suggesting limited short-term clinical utility.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Doi Y, Shinzawa M, Arisato T, et al. Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis. Kidney Int Rep. 2025. PMID: 41541789. doi:10.1016/j.ekir.2025.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。